13 Publicly Traded Companies Developing Longevity Therapeutics
Aging research shifted from watching what happens to testing what can be changed. In the 1930s, lab studies in rats showed that eating fewer calories without malnutrition extended life —a first signal that lifespan is adjustable.
In the 1990s, work in tiny worms found that a single gene involved in hormone-like signaling could double lifespan. That result made aging look like a biological program that cells regulate, not just wear and tear. Drug studies in mice came next. Blocking a growth pathway called mTOR with rapamycin extended lifespan even when treatment began late in life. This put a specific pathway on the map for age-related interventions.
Another thread focused on “senescent” cells—older, damaged cells that linger. Clearing these cells in mice delayed several age-related problems and improved function. The idea moved from theory to a testable strategy. Measurement tools caught up: DNA methylation “clocks” estimate biological age from blood or tissue, giving researchers a way to track whether an intervention is pushing aging faster or slower. In a randomized human study, long-term calorie reduction produced signs of a slower pace of biological aging on these measures.
Thus, some early clinical signals are emerging. For example, short courses of mTOR-pathway inhibition boosted flu vaccine responses in older adults. Small pilot studies of senolytic drugs reported feasibility and shifts in relevant biomarkers in diabetic kidney disease and idiopathic pulmonary fibrosis. These do not prove longer life, but they show how geroscience is being tested in people.
The companies profiled below build on this arc—turning established findings into therapies aimed at extending healthy years.
Disclaimer: This post is not investment advice of any kind; it is for informational purposes only. Neither BPT Analytics Ltd nor the authors of this post endorse or recommend any particular stocks or investment opportunities. Consult relevant professional service providers for any investment decisions at all times.
BioAge Labs, Inc. (NASDAQ: BIOA)
US-based BioAge Labs, founded in 2015 and headquartered in Richmond, California, is a clinical-stage biopharmaceutical company developing therapies that target molecular drivers of aging and age-associated diseases. The company went public on Nasdaq in September 2024, raising $198 million.
BioAge uses a proprietary human longevity data platform built on longitudinal multi-omic datasets and detailed health records from large human cohorts, including biobank studies such as the Age Labs collaboration, which included >17,000 samples from 6,000+ HUNT Biobank participants, with follow-up spanning several decades. By applying AI and other data science methods to these datasets, the platform links molecular signatures to trajectories of healthy aging, disease resilience, functional decline, and mortality risk, and prioritizes targets that appear causally tied to metabolic aging.
These insights feed into programs in metabolic and inflammatory disease, including an oral, brain-penetrant NLRP3 inhibitor (BGE-102) currently in Phase 1 trial and a portfolio of APJ agonists based on exercise biology that act as pharmacological “exercise mimetics,” roughly doubling GLP-1–induced weight loss while improving muscle function and cardiometabolic endpoints in animal studies.
BioAge also expanded its APJ program by securing an exclusive option agreement with JiKang to jointly advance a reportedly ≥10-fold-more-potent-than-apelin APJ agonist nanobody up to the start of IND-enabling studies. Other collaborations include a multi-year collaboration with Novartis that leverages the platform to discover additional targets for age-related conditions and a Lilly ExploR&D agreement for antibody development in metabolic aging.
Biophytis, S.A. (US OTC ADR: BPTSY)
Biophytis is a French biotech company founded in 2006. They aim to slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with active programs in sarcopenia, obesity-related muscle wasting alongside GLP-1 use, and DMD.
Biophytis closed a $20.1 million IPO in February 2021. In April 2024, Biophytis delisted from Nasdaq on Apr 26, 2024 and now trades over-the-counter. The company’s ordinary shares are listed on Euronext Growth Paris (ALBPS).
Their most advanced clinical program is BIO101, a treatment for sarcopenia, an age-related skeletal muscle degeneration condition. In 2023, FDA authorized initiation of Phase 3 SARA-31; in 2025 the company outlined a Phase 3 strategy in Europe and Asia, targeting ~932 patients and announced plans to finance via a Hong Kong JV.
BIO101 is also being developed as a treatment for treating muscle loss linked to obesity, because current weight-loss drugs often cause both fat and muscle loss. The candidate is supported by preclinical data showing improved mobility and grip strength in mice and a Phase 2 trial is planned, enrolling 164 semaglutide-treated patients. Recently, Biophytis received authorization from the European Medicines Agency to begin the Phase 2 clinical trial.
Geron (NASDAQ:GERN)
Geron is a telomerase-focused biopharmaceutical company working at the intersection of blood cancer treatment and the biology of aging. Built on Nobel Prize–recognized discoveries about telomerase and telomeres, the company develops drugs that inhibit telomerase, an enzyme linked both to malignant cell immortality and to fundamental mechanisms of cellular aging. Geron went public in 1996, with a recent pricing of $198 million upsized public offering of common stock and pre-funded warrants.
Active programs include an approved therapy for transfusion-dependent lower-risk myelodysplastic syndromes and a pivotal study in myelofibrosis. Their lead program, lower-risk MDS with transfusion-dependent anemia, is designed to help patients need fewer blood transfusions. Imotelstat (Rytelo) received U.S. approval in 2024 and European Commission approval on March 11, 2025.
The myelofibrosis program is aimed at cancer in older adults. Median age at diagnosis is mid-to-late 60s, so any survival or symptom gains primarily benefit an aging population. The Phase 3 IMpactMF study uses overall survival as its primary endpoint in patients who failed JAK inhibitors.
Longeveron (NASDAQ:LGVN)
Longeveron is a Miami-based clinical-stage regenerative medicine company developing allogeneic cell therapies for aging-related and life-threatening conditions. Founded in 2014 the company went public in 2021 with a $26.6 million upsized IPO.
Longeveron’s work centers on laromestrocel (Lomecel-B), an off-the-shelf product derived from culture-expanded mesenchymal stem cells (MSCs) sourced from the bone marrow of young healthy adult donors.
Laromestrocel is being evaluated across three main indications—mild Alzheimer’s disease, aging-related frailty and hypoplastic left heart syndrome (HLHS), a rare pediatric heart defect. Longeveron has completed multiple early-stage trials in these areas, including Phase 1 and 2 studies in Alzheimer’s and aging-related frailty and a Phase 1 study in HLHS. In mild Alzheimer’s disease, a Phase 2a trial reported signals of benefit on cognitive measures, quality of life and brain volume, supporting plans for a single pivotal Phase 2/3 study, while the HLHS program is advancing through a Phase 2b trial after receiving Orphan Drug, Fast Track and Rare Pediatric Disease designations.
Mechanistically, Longeveron positions laromestrocel as a multi-modal MSC therapy with pro-vascular, pro-regenerative and anti-inflammatory properties that may address several hallmarks of aging, including immune dysregulation, chronic inflammation and vascular dysfunction.
Denali Therapeutics, Inc. (NASDAQ: DNLI)
San-Francisco-based Denali Therapeutics is developing drugs for neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and ALS. Founded in 2013, the company went on IPO in 2017, banking a total of $250 million.
Delani’s drug candidates are engineered with the aim of optimizing brain delivery. The company develops blood-brain barrier (BBB)-penetrant biologics and oligonucleotides using its Transport Vehicle platform. Its technology uses a modified antibody fragment designed to attach to a natural receptor on blood vessel cells, allowing the drug to be carried across the barrier and released inside the brain.
Denali is currently advancing several clinical programs aimed at treating rare and neurodegenerative diseases. Its lead therapy for Hunter syndrome is under FDA review for accelerated approval, while other trials are progressing in conditions such as Sanfilippo syndrome, frontotemporal dementia, Alzheimer’s disease, Pompe disease, and Parkinson’s disease.
One of the drug candidates—LRRK2 for Parkinson's disease—is developed in partnership with Biogen; the program is advancing with a fully enrolled Phase 2b LUMA and Phase 2a BEACON in LRRK2-PD. Delani also has another partnership with Sanofi on the small-molecule drug for cutaneous lupus erythematosus (CLE), which underwent Phase 2 study in 2021. With Takeda, Denali’s active program is DNL593/TAK-594 for frontotemporal dementia with GRN gene mutations (FTD-GRN), with Phase 1/2 ongoing.
FOXO Technologies (OTC:FOXO)
FOXO Technologies is a US-based biotech company founded in 2016, merging epigenetics with artificial intelligence (AI) to improve longevity. They went public in September 2022, banking a total of $201 million and in August 2025 its shares moved from NYSE American to OTC after NYSE delisting proceedings.
FOXO uses advanced machine learning to examine thousands of models to find patterns of DNA methylation that measure human health, wellness, disease, and aging. The company claims its data is prepped, quality-checked, and organized via custom bioinformatics pipelines.
FOXO licensed the epigenetic clocks developed in the Horvath Lab at UCLA for use in actuarial predictive modeling and underwriting. The Mortality Predictor EEAA estimates biological aging based on human methylation patterns; PhenoAge is an epigenetic biomarker of aging that measures healthspan regarding predictions for various aging-related diseases. Finally, GrimAge is a measure of epigenetic age, acceleration of aging, that strongly measures all-cause mortality.
In July 2025 FOXO announced plans to spin off its epigenetics subsidiary, FOXO Labs, which houses the methylation/AI platform and the UCLA licenses for PhenoAge and GrimAge clocks used in financial-services modeling.
GenSight Biologics, S.A. (EPA: SIGHT)
GenSight is a French company developing gene therapy-based treatments for retinal degenerative diseases. Founded in 2012, the company went on IPO in 2016, banking a total of $44 million.
Besides gene therapy, GenSight also uses Mitochondrial Targeting Sequence (MTS) technology, which shuttles nuclear messenger RNA directly to the mitochondrial surface and imports newly synthesized proteins into the mitochondrial matrix. Another platform is based on optogenetics—a biological technique that involves the transfer of a gene encoding a light-sensitive protein to cause neuronal cells to respond to light stimulation.
Leber Hereditary Optic Neuropathy (LHON) is a rare genetic disorder caused by mutations in mitochondrial genes that help produce energy in cells. These mutations, most often in the ND4 gene, damage the retinal ganglion cells in the eye, which are responsible for sending visual signals to the brain. As these cells lose their ability to function, patients gradually lose vision most often between the ages of 15 and 35. The resulting vision loss is severe and permanent.
The company’s lead asset, LUMEVOQ for LHON, had its EMA application withdrawn in April 2023. However, the company now plans a new pivotal Phase 3 study RECOVER to generate additional efficacy/safety data before a future refiling. Additionally, in Oct 2025, the US authorized individual patient expanded access to LUMEVOQ.
Genflow Biosciences, PLC (LSE: GENF)
UK-based Genflow Biosciences was founded in 2020, going public in January 2022 with a $4.8 million IPO.
Genflow is dedicated to developing and commercializing novel therapeutics targeting aging in dogs and humans. Their lead compound GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion, aimed at slowing aging and addressing metabolic-associated steatohepatitis (MASH). The candidate is currently advancing toward pre-IND. Its other active programs include gene therapies for Werner syndrome, age-related decline in dogs, sarcopenia, and ocular diseases.
According to the June 2025 corporate update, the company collaborates with institutions such as CER Groupe, Université libre de Bruxelles, Revatis, Syngene, and Heureka Labs, combining gene therapy research with AI-based genomic analysis and organoid modeling. These partnerships and government-backed grants in Wallonia support Genflow’s efforts to translate its SIRT6 technology into clinical applications.
At the same time, the non-human pipeline for the anti-aging therapy for dogs is in the preclinical stages, with GF-1004 (canine aging POC) having an ongoing clinical trial in elderly dogs. A recent August update reported no adverse effects across three SIRT6 delivery modalities.
Mesoblast, Ltd. (NASDAQ: MESO)
Melbourne-based Mesoblast develops biologic products for regenerative medicine applications. After being founded in 2004, the company listed on Nasdaq in 2015, banking a total of $68.3 million.
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standards of care.
The company’s lead product Ryoncil (remestemcel-L-rknd) won US FDA approval in 2024 for pediatric steroid-refractory acute graft versus host disease (acute GVHD). Mesoblast is also advancing its second lead candidate, Revascor (rexlemestrocel-L), toward potential accelerated FDA approval for ischemic heart failure with reduced ejection fraction. MPC-06-ID for chronic low back pain due to degenerative disc disease remains a Phase 3 candidate.
At the same time, the company is working with the NIH-backed Bone Marrow Transplant Clinical Trials Network to expand Ryoncil’s approved use from children to adults with steroid-refractory acute graft-versus-host disease.
Pluri Inc. (formerly Pluristem Therapeutics, Inc.) (NASDAQ: PLUR)
Israel-based Pluri uses placental cells and a 3D technology platform to develop cell therapies for diseases. The company was founded in 2003 and almost immediately went public.
Pluri aims to check multiple portfolio boxes, such as pharma, food tech, agri-tech, and biologics. They are creating products that improve human health and well-being and increase environmental sustainability, with Ever After Foods (cultivated meat/fish), Kokomodo (cacao), Coffeesai (coffee), plus the Contract Development and Manufacturing Organization (CDMO) division. Recently Pluri received a patent for its 3D bioreactor system for plant cell cultivation, supporting its PluriAgtech division and cell-based coffee development. Ever After Foods also raised $10M in 2024.
Pluri’s lead asset is PLX-PAD, an allogeneic placental-cell therapy being studied for musculoskeletal regeneration—most recently a Charité-led Phase I/IIa in knee osteoarthritis, a driver of frailty and loss of independence in older adults (PROTO project). A second program, PLX-R18, targets hematopoietic acute radiation syndrome under the FDA’s Animal Rule and holds Orphan Drug status; it addresses resilience of blood-cell production, a core aging pathway in stress settings
Scholar Rock, Inc. (NASDAQ: SRRK)
Scholar Rock is a US-based biopharmaceutical company developing new medicines and treatments for various degenerative diseases and cancer. Founded in 2012, the company went on IPO in 2018, banking a total of $75 million.
Scholar Rock uses its technology platform and structural insights to discover new medicines designed to selectively target the precursor, or inactive, forms of growth factors to avoid toxicity and improve efficacy.
The company has a portfolio with nine drug candidate pipelines, out of which four are for treating degenerative diseases. The lead candidate is apitegromab, a selective inhibitor of the activation of latent myostatin, which met the Phase 3 SAPPHIRE primary endpoint for spinal muscular atrophy and recently moved to filing. The FDA issued a CRL on Sept 23, 2025 tied to observations at Catalent’s Indiana fill-finish site, with a resubmission planned after remediation.
Scholar Rock also reported Phase 2 EMBRAZE data showing lean-mass preservation during tirzepatide-induced weight loss, supporting a cardiometabolic path. Oncology candidate SRK-181 (latent TGFβ1) completed Phase 1 DRAGON with updated data at ASCO 2024.
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO)
Telomir Pharmaceuticals is a US-based preclinical-stage company, founded in 2021, that focuses on age-reversal therapeutics rooted in telomere biology. The company listed on Nasdaq in February 2024, raising roughly $7 million IPO.
Telomeres are protective caps at the ends of chromosomes that get shorter each time a cell divides. Telomere biology studies how these caps are maintained or lost over time, how that shortening is linked to cell aging and loss of function, and how manipulating telomere length or the telomerase enzyme might slow or reverse some cellular aging processes.
Telomir’s lead asset, Telomir-1, is an oral small-molecule candidate that aims to slow cellular aging by acting on several basic stress pathways in cells. The drug is designed to help keep telomeres from wearing down too quickly, while also fine-tuning how cells handle metals like iron and copper that can drive oxidative damage when out of balance.
The company reports that Telomir-1 is being developed to reduce oxidative stress, DNA damage, chronic inflammation, and mitochondrial dysfunction, with the long-term goal of applying it across common age-linked conditions such as type 2 diabetes, cancer, Alzheimer’s disease, and macular degeneration, as well as selected rare disorders tied to metal metabolism and premature aging. In preclinical models, Telomir-1 extended telomere length, reset epigenetic aging markers, improved muscle and weight parameters and restored normal survival in an accelerated-aging progeria model.
The current plan is to complete chemistry, pharmacology, ADME, and toxicology studies through 2025 and then move Telomir-1 into first-in-human testing after an IND submission targeted for late 2025
Vaxxinity, Inc. (OTC: VAXX)
Vaxxinity is a US-based clinical-stage biotech founded in 2019 that develops synthetic peptide–based active immunotherapies for chronic, age-related diseases, with a focus on neurodegeneration and cardiometabolic risk. The company went on IPO in November 2021, banking a total of $78 million. In April 2024 Vaxxinity announced it would voluntarily delist and deregister its Class A common stock and its shares now trade over the counter on the OTC Expert Market.
Vaxxinity’s technology uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome “immune tolerance,” or the immune system's tendency to avoid attacking harmful molecules within the human body. The pipeline targets beta-amyloid (Alzheimer’s disease), alpha-synuclein (Parkinson’s disease and related synucleinopathies), tau (tauopathies), CGRP (migraine), PCSK9 (hypercholesterolemia), and SARS-CoV-2.
The most advanced drug candidate is the UB-311 program for Alzheimer’s disease, with Phase 2a data for Alzheimer’s vaccine UB-311 showing the candidate was generally well tolerated, supporting its FDA Fast Track status. Another vaccine, UB-312, completed a Phase 1 trial demonstrating exploratory improvements in motor function in Parkinson’s disease. UB-313, a vaccine for preventive treatment of migraine, entered a randomized Phase 1 study with first subjects dosed in 2022. In cardiometabolic disease, PCSK9 vaccine candidate VXX-401 for hypercholesterolemia advanced into a first-in-human Phase 1 trial.
